ArticlebioRxiv : the preprint server for biology2025
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.
Anmbreen Jamroze et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.